Table III.
Prognostic factors for survival post achievement of response.
| Characteristic | Category | Median survival (months) | 1-year survival (%) | p-value |
|---|---|---|---|---|
| Age (years) | <32 (median) | 11 | 49 | 0.07 |
| 32–49 | 10 | 42 | (0.02 at cut-off 50 years) | |
| 50–59 | 5 | 27 | ||
| ≥60 | 8 | 35 | ||
| Response to salvage | S1-CR | 11 | 45 | 0.01 |
| S2-CR | 7 | 33 | ||
| Duration of first CR (months) | 0 | 10 | 44 | 0.004 |
| 1–11 | 7 | 25 | ||
| 12–36 | 11 | 51 | ||
| >36 | 20 | 65 | ||
| Karyotype | Diploid | 11 | 44 | 0.008 |
| Philadelphia-positive | 8 | 30 | ||
| Other (including IM) | 11 | 47 | ||
| Not done | 8 | 43 | ||
| Hemoglobin (g/dL) | <10 | 9 | 38 | 0.02 |
| 10–11.9 | 8 | 36 | ||
| ≥12.0 | 12 | 51 | ||
| WBC (× 109/L) | <5.0 | 10 | 46 | 0.0004 |
| 5–9.9 | 16 | 60 | ||
| ≥10 | 7 | 24 | ||
| Platelets (× 109/L) | <25 | 6 | 31 | 0.046 |
| 25–49 | 11 | 48 | ||
| 50–100 | 8 | 34 | ||
| >100 | 11 | 46 | ||
| Albumin (g/L) | <3.8 | 9 | 39 | 0.007 |
| ≥3.8 | 11 | 46 | ||
| Year of study | 1990–2000 | 11 | 46 | 0.24 |
| 2001–2007 | 8 | 38 | ||
| Salvage producing remission | VAD–Hyper-CVAD | 11 | 47 | 0.01 |
| Cytarabine combination | 8 | 30 | ||
| Allogeneic transplant | 9 | 36 | ||
| Other | 9 | 40 | ||
| Marrow blast (%) | <20 | 11 | 51 | 0.01 |
| 20–50 | 7 | 21 | ||
| >50 | 11 | 45 | ||
| Peripheral blast (%) | ≤1 | 11 | 47 | 0.08 |
| >1 | 9 | 38 | ||
| LDH (IU/L) | ≤672 | 12 | 52 | 0.03 |
| >672 | 9 | 33 |
S1 = salvage 1; S2 = salvage 2; CR, complete response; WBC, white blood cell count; LDH, lactate dehydrogenase; IM, insufficient metaphases; VAD, vincristine, doxorubicin, and dexamethasone; Hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone.